Experimental feature

Listen to this article

00:00
00:00
Experimental feature
or

Pfizer, the world’s top drugmaker by revenues, will de-list from the London and Swiss stock exchanges.

In an announcement on Wednesday, the company said it had applied to cancel shares on the London Stock Exchange, while the SIX Swiss Exchange said Pfizer’s secondary shares worth 5 US cents each would be cancelled following a request from the company made yesterday.

The company said it took the decision due to “limited trading or liquidity” of its shares on the LSE.

Pfizer’s main stock listing is in New York.

Copyright The Financial Times Limited 2017. All rights reserved.
myFT

Follow the topics mentioned in this article

Follow the authors of this article

Comments have not been enabled for this article.